Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation

To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Undas, Anetta, Drabik, Leszek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141434/
https://www.ncbi.nlm.nih.gov/pubmed/31911561
http://dx.doi.org/10.14744/AnatolJCardiol.2019.30766
_version_ 1783519191679107072
author Undas, Anetta
Drabik, Leszek
author_facet Undas, Anetta
Drabik, Leszek
author_sort Undas, Anetta
collection PubMed
description To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing, while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and current expert opinion on this subject have been summarized in this review article.
format Online
Article
Text
id pubmed-7141434
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-71414342020-04-13 Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation Undas, Anetta Drabik, Leszek Anatol J Cardiol Review To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing, while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and current expert opinion on this subject have been summarized in this review article. Kare Publishing 2020-01 2019-12-05 /pmc/articles/PMC7141434/ /pubmed/31911561 http://dx.doi.org/10.14744/AnatolJCardiol.2019.30766 Text en Copyright: © 2020 Turkish Society of Cardiology http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Review
Undas, Anetta
Drabik, Leszek
Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
title Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
title_full Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
title_fullStr Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
title_full_unstemmed Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
title_short Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
title_sort non-vitamin k antagonist oral anticoagulants in cancer patients with atrial fibrillation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141434/
https://www.ncbi.nlm.nih.gov/pubmed/31911561
http://dx.doi.org/10.14744/AnatolJCardiol.2019.30766
work_keys_str_mv AT undasanetta nonvitaminkantagonistoralanticoagulantsincancerpatientswithatrialfibrillation
AT drabikleszek nonvitaminkantagonistoralanticoagulantsincancerpatientswithatrialfibrillation

Ejemplares similares